Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2013, Article ID 835316, 3 pages
http://dx.doi.org/10.1155/2013/835316
Case Report

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report

Department of Obstetrics and Gynecology, Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA

Received 7 January 2013; Accepted 28 January 2013

Academic Editors: E. Cosmi, C. S. Hsu, T. Levy, and E. Shalev

Copyright © 2013 Christie Walker and Shawky Z. A. Badawy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. CDC, “The Great Public Health achievements—United States, 1900–1999,” Morbidity and Mortality Weekly Report, vol. 48, no. 12, pp. 241–243, 1999. View at Google Scholar
  2. “Injectable contraceptives,” in Contraceptive Technologies., R. A. Hatcher, J. Trussell, and A. Nelson, Eds., pp. 157–180, Ardent Media, New York, NY, USA, 19th edition, 2008.
  3. W. D. Mosher, G. M. Martinez, A. Chandra, J. C. Abma, and S. J. Willson, “Use of contraception and use of family planning services in the United States: 1982–2002,” Advance Data, no. 350, pp. 1–36, 2004. View at Google Scholar · View at Scopus
  4. S. Haider and P. D. Darney, “Injectable contraception,” Clinical Obstetrics and Gynecology, vol. 50, no. 4, pp. 898–906, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Polaneczky and M. Liblanc, “Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents,” Journal of Adolescent Health, vol. 23, no. 2, pp. 81–88, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Said, W. Sadek, M. Rocca et al., “Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World health organization, special programme of research, development and research training in human reproduction, task force on long-acting systemic agents for fertility regulation,” Human Reproduction, vol. 11, supplement 2, pp. 1–13, 1996. View at Google Scholar · View at Scopus
  7. R. D. Smith, B. A. Cromer, J. R. Hayes, and R. T. Brown, “Medroxyprogesterone acetate (Depo-Provera) use in adolescents: uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates,” Adolescent and Pediatric Gynecology, vol. 8, no. 1, pp. 24–28, 1995. View at Google Scholar · View at Scopus
  8. J. Suckling, R. Kennedy, A. Lethaby, and H. Roberts, “Local oestrogen for vaginal atrophy in postmenopausal women,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD001500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. U.S. National Library of Medicine, “Drug and Safety Information. Depo-Medroxyprogesterone Acetate,” 2012, http://dailymed.nlm.nih.gov/dailymed/.
  10. Pfizer, “Prescription drug labels. Depo-Provera,” 2012, http://labeling.pfizer.com/ShowLabeling.aspx?id=522.
  11. Food and Drug Administration, “Access Data. Depo-Provera prescribing information,” 2012, http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154784.htm.
  12. M. L. Krychman, “Vaginal estrogens for the treatment of dyspareunia,” Journal of Sexual Medicine, vol. 8, no. 3, pp. 666–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Schneider, E. Friedrich, and A. E. Schindler, “Hormonal cytology: a correlation with plasma estradiol, measured by radioimmunoassay,” Acta Cytologica, vol. 21, no. 1, pp. 37–39, 1977. View at Google Scholar · View at Scopus
  14. B. McEndree, “Clinical application of the vaginal maturation index,” The Nurse Practitioner, vol. 24, no. 9, pp. 48–56, 1999. View at Google Scholar · View at Scopus